In the following video, Motley Fool health care analyst David Williamson talks about Pfizer's (NYSE:PFE) earnings report. He details how the company managed to cut costs and shore up emerging market sales -- leading to it beating expectations this quarter -- despite the loss of patent protection for its cardiovascular disease prevention drug Lipitor, which was once the greatest-selling drug of all time.

David Williamson owns shares of Pfizer. Follow him on Twitter @MotleyDavid. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.